---
title: 'Therapeutic Drug Monitoring in Children and Adolescents: Findings on Fluoxetine
  from the TDM-VIGIL Trial'
date: '2023-09-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37765171/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230928180748&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Fluoxetine is the recommended first-line antidepressant in many therapeutic
  guidelines for children and adolescents. However, little is known about the relationships
  between drug dose and serum level as well as the therapeutic serum reference range
  in this age group. Within a large naturalistic observational prospective multicenter
  clinical trial ("TDM-VIGIL"), a transdiagnostic sample of children and adolescents
  (n = 138; mean age, 15; range, 7-18 years; 24.6% males) was treated with ...
disable_comments: true
---
Fluoxetine is the recommended first-line antidepressant in many therapeutic guidelines for children and adolescents. However, little is known about the relationships between drug dose and serum level as well as the therapeutic serum reference range in this age group. Within a large naturalistic observational prospective multicenter clinical trial ("TDM-VIGIL"), a transdiagnostic sample of children and adolescents (n = 138; mean age, 15; range, 7-18 years; 24.6% males) was treated with ...